Pneumococcal carriage and disease in adults in England 2011-2019: the importance of adults as a reservoir for pneumococcus in communities.

adults carriage children invasive pneumococcal disease pneumococcal transmission

Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
16 Jul 2024
Historique:
received: 08 03 2024
revised: 01 07 2024
accepted: 09 07 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 16 7 2024
Statut: aheadofprint

Résumé

Pneumococcal carriage in children has been extensively studied, but carriage in healthy adults and its relationship to invasive pneumococcal disease (IPD) is less understood. Nasal wash samples from adults without close contact with young children (Liverpool, UK), 2011-2019, were cultured, and culture-negative samples tested by PCR. Pneumococcal carriage in adults 18-44 years was compared with carriage among PCV-vaccinated children 13-48 months (nasopharyngeal swabs, Thames Valley, UK) and IPD data for England for the same ages for 2014-2019. Age-group specific serotype invasiveness was calculated and used with national IPD data to estimate carriage serotype distributions for adults aged 65+ years. In total 98 isolates (97 carriers) were identified from 1,631 adults aged 18+ years (age and sex standardized carriage prevalence 6.4%), with only three identified solely by PCR. Despite different carriage and IPD serotype distributions between adults and children, serotype invasiveness was highly correlated (R=0.9). Serotypes 3, 37 and 8 represented a higher proportion of adult carriage than expected from direct low-level transmission from children to adults. The predicted carriage serotype distributions for 65+ years aligned more closely with the carriage serotype distribution for young adults than young children. The nasal wash technique is highly sensitive; additional benefit of PCR is limited. Comparison of carriage serotype distributions suggests some serotypes may be circulating preferentially within these specific young adults. Our data suggest that for some serotypes carried by adults 65+ years, other adults may be an important reservoir for transmission. Age groups such as older children should also be considered.

Sections du résumé

BACKGROUND BACKGROUND
Pneumococcal carriage in children has been extensively studied, but carriage in healthy adults and its relationship to invasive pneumococcal disease (IPD) is less understood.
METHODS METHODS
Nasal wash samples from adults without close contact with young children (Liverpool, UK), 2011-2019, were cultured, and culture-negative samples tested by PCR. Pneumococcal carriage in adults 18-44 years was compared with carriage among PCV-vaccinated children 13-48 months (nasopharyngeal swabs, Thames Valley, UK) and IPD data for England for the same ages for 2014-2019. Age-group specific serotype invasiveness was calculated and used with national IPD data to estimate carriage serotype distributions for adults aged 65+ years.
RESULTS RESULTS
In total 98 isolates (97 carriers) were identified from 1,631 adults aged 18+ years (age and sex standardized carriage prevalence 6.4%), with only three identified solely by PCR. Despite different carriage and IPD serotype distributions between adults and children, serotype invasiveness was highly correlated (R=0.9). Serotypes 3, 37 and 8 represented a higher proportion of adult carriage than expected from direct low-level transmission from children to adults. The predicted carriage serotype distributions for 65+ years aligned more closely with the carriage serotype distribution for young adults than young children.
CONCLUSIONS CONCLUSIONS
The nasal wash technique is highly sensitive; additional benefit of PCR is limited. Comparison of carriage serotype distributions suggests some serotypes may be circulating preferentially within these specific young adults. Our data suggest that for some serotypes carried by adults 65+ years, other adults may be an important reservoir for transmission. Age groups such as older children should also be considered.

Identifiants

pubmed: 39013016
pii: 7714969
doi: 10.1093/infdis/jiae351
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Auteurs

D El Safadi (D)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

L Hitchins (L)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

A Howard (A)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

P Aley (P)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford, United Kingdom.

J Bowman (J)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

M Bertran (M)

Immunisations and Vaccine Preventable Diseases, UK Health Security Agency (UKHSA), London, United Kingdom.

A Collins (A)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

R Colin-Jones (R)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

F Elterish (F)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

N K Fry (NK)

Immunisations and Vaccine Preventable Diseases, UK Health Security Agency (UKHSA), London, United Kingdom.

S B Gordon (SB)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

K Gould (K)

Institute for Infection and Immunity, St George's University, London, United Kingdom.
BUGS Bioscience, London Bioscience Innovation Centre, London, United Kingdom.

J Hinds (J)

Institute for Infection and Immunity, St George's University, London, United Kingdom.
BUGS Bioscience, London Bioscience Innovation Centre, London, United Kingdom.

E Horn (E)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

A Hyder-Wright (A)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

R Kandasamy (R)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

S Ladhani (S)

Immunisations and Vaccine Preventable Diseases, UK Health Security Agency (UKHSA), London, United Kingdom.

D Litt (D)

Immunisations and Vaccine Preventable Diseases, UK Health Security Agency (UKHSA), London, United Kingdom.

E Mitsi (E)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

A Murphy (A)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

A J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

E Plested (E)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford, United Kingdom.
National Institute for Health Research Clinical Research Network, Thames Valley and South Midlands, Oxford, United Kingdom.

S Pojar (S)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

H Ratcliffe (H)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

M C Robertson (MC)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

H Robinson (H)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford, United Kingdom.
National Institute for Health Research Clinical Research Network, Thames Valley and South Midlands, Oxford, United Kingdom.

M D Snape (MD)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford, United Kingdom.

C Solórzano (C)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

M Voysey (M)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

E Begier (E)

Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.

J Catusse (J)

Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.

M Lahuerta (M)

Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.

C Theilacker (C)

Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.

B D Gessner (BD)

Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.

K S Tiley (KS)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

D M Ferreira (DM)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Classifications MeSH